NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING & PATHOLOGY DETECTION: Showcasing optical coherence tomography ...

Diseases that affect the retina, the light-sensitive layer at the back of the eye, are a significant cause of visual impairment and blindness. Gene therapy holds promise for treating some of these ...

CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that EDIT-101 ...

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...

When the FDA approved Spark Therapeutics’ Luxturna in December 2017, gene therapy became a household concept. Chatter about gene therapy curing blindness became hot fodder at dinner tables and ...

Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP, BCVA ...

Please provide your email address to receive an email when new articles are posted on . Central serous chorioretinopathy is a common chorioretinal disease characterized by a buildup of subretinal ...

“Currently, there is a lack of evidence-based research and rigorous guidelines for the management of patients with SMH secondary to nAMD [neovascular AMD],” said Dr. Gabrielle, who is based at the ...

The subretinal mode of injection involves the injection of the vector in the subretinal space between the layer of photoreceptors and the retinal pigment epithelium. Delivery of vectors via the ...